Navigation Links
Mainz University Medical Center receives further DFG funding for cardiovascular research
Date:1/29/2013

The German Research Foundation (DFG) has again approved funding for the Department of Internal Medicine II of the Mainz University Medical Center to promote cardiovascular research for the second time within only a few weeks. The aim of the project currently being sponsored is to investigate the relationships between free radicals and disorders of the cardiovascular system. The team, led by biologist Dr. Swenja Krller-Schn and PD Dr. Eberhard Schulz, senior physician at the Department of Internal Medicine II of the Mainz University Medical Center, has a particular interest in how specific enzyme systems regulate vascular function. These significantly influence the formation of free radicals, inflammatory reactions, and vascularization. It is thus hoped that the results of this theoretical research will make it possible to diagnose vascular diseases at an even earlier stage and to intervene with targeted treatment to prevent related complications, such as myocardial infarction. The researchers intend to spend the approximately EUR 210,000 funding granted over the next two years on human resources and consumables.

In this project, the research team will be studying to what extent molecules that control the energy consumption of cells also have a long-term effect on vascular function. "This correlation seems to make sense because when energy reserves decrease, cells need to be supplied with substrates in the blood stream and, for this purpose, adequate dilation of the blood vessels is necessary. However, the correlations between the mechanisms involved in this process have still not been sufficiently explained," stated Krller-Schn and Schulz.

The successful acquisition of third-party funds is also attributable to the strategy adopted by the University Medical Center, namely that of establishing specialized research units. Within this context, the research team led by Dr. Swenja Krller-Schn and PD Dr. Eberhard Schulz has managed to form partnerships that are important for the future of translational medicine. "We are pleased that the German Research Foundation has recognized our achievements and has decided to sponsor us. The work of the Research Unit Vascular Prevention and the establishment of the Center for Thrombosis and Hemostasis (CTH) with the support of the Mainz Heart Foundation have created an environment in which applications have a greater chance of success," said Prof. Dr. Thomas Mnzel, Coordinator of the Research Unit Vascular Prevention at Mainz University Medical Center.


'/>"/>

Contact: Swenja Krller-Schn
swenja.kroeller-schoen@gmx.de
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related medicine news :

1. DFG funds new Collaborative Research Center at the Mainz University Medical Center
2. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
3. Scientists at the Mainz University Medical Center gain new insights into Taspase1 function
4. University of Tennessee researcher finds first time could predict sexual satisfaction
5. Lavender Languages Conference celebrates 20 years at American University
6. Spring Classes for Wexford University’s Online Doctoral Degree in Applied Sport Psychology Begin April 1
7. To Meet Growing Demand for Sports Psychology Experts, Wexford University Offers Master’s Degree in Applied Sport Psychology: Classes Begin April 1
8. Wexford University’s Master’s Degree in Nutrition and Exercises Prepares Weight Management Coaches and Consultants: Spring Quarter Launches April 1
9. Wayne State University researcher to evaluate success of text message diabetes intervention
10. University of Southern Mississippi Department of Marine Science Researches Marine Algae as Alternative Fuel Source
11. McGill University Launches a Major New Study on HPV Prevention Using Divine 9 Personal Lubricants with Carragel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... for large animal healthcare products, is introducing Flexadin UCII, part of the EQUISTRO ... cartilage development and joint health in horses at the immunologic level. , The ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: